

Remarks

Claims 1 to 19 were pending as amended by the prior Amendment and are here indicated as entered. By this Amendment, only new claim 20 has been added. New claim 20 represents to claim 9 before the prior amendment. As no new matter has been added thereby, entry of the amendment is respectfully requested. Claims 1, 2, 4, 5, 9, and 12 to 20, as amended, are now pending.

Based on the prior Amendment Remarks and submission, Reidel *et al.* (U.S. Patent App. Pub. No. 2004/0259925) should not be used as a reference against claim 20. Furthermore, claim 20 is patentable over Nakatani *et al.* (U.S. Patent App. Pub. No. 2004/010813), Donsbach *et al.* (U.S. Patent App. Pub. No. 2003/0130331), and Lacourciere *et al.* (American J. Therapeutics 2002, 9(2), pages 111-7) because none of them specifically teach a crystalline telmisartan sodium salt in combination with the excipients specified.

Applicant submits that all the pending claims are allowable and respectfully solicits a Notice of Allowance for all of the pending claims. If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Respectfully submitted,

/timothy witkowski/

Timothy X. Witkowski
Registration No. 40,232
Attorney for Applicant

BOEHRINGER INGELHEIM CORPORATION
Patent Department
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Telephone: (203) 798-4310
Facsimile: (203) 798-4408